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SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: 
the clinical illness COVID-19. With only one authorized drug for emergency 
use in critically ill patients: Remdesivir, there is not any other approved drug 
or vaccine yet with proven potential to overcome this infection. We exposed 
here many scientific evidences to support our novel idea that a macrolide, 
basically Clarithromycin, could be effective as a single agent for treatment 
and prophylaxis of COVID-19. Clarithromycin could change the history of 
this pandemic. It could reduce the costs of treatment and the potential ad-
verse effects when combining more than one drug such as with Hydroxych-
loroquine. Clarithromycin treatment and prophylaxis as a single agent could 
be much more simple, safe and cheaper as giving Chloroquine or Hydrox-
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1. Introduction 
SARS-CoV-2 (previously named 2019-nCoV), the virus that causes the clinical 
illness COVID-19, is a novel RNA virus belonging to the coronavirus family [1]. 
With more than three million confirmed cases worldwide and more than 
200,000 deaths at this moment and growing up these numbers constantly, vari-
ous treatments are being tried clinically or undergoing evaluation [1] [2] [3] [4]. 
The greatest risk of spread worldwide of Covid-19 involves serious life-threatening 
problems against human security. Fever, cough, and shortness of breath are the 
main symptoms of the disease that can lead to pneumonia or other organs com-
promised with a mortality rate of 5% or higher [1] [2] [5]. Currently, there is 
only one authorized drug, but for emergency use in critically ill patients: Remde-
sivir [6]. There are no other approved medications for infectious coronavirus, 
despite the fact that antiviral drugs such as protease inhibitors, integrase and/or 
polymerase enzymes are designed and are in advanced studies [3] [4] [7]. 
Among these inhibitors, antiprotease inhibitors appear to work effectively in 
blocking virus replication and provide promising treatment for Covid19 disease 
but not yet advisable in a systematic way [3] [8] [9]. The majority of published 
evidence that has suggested treatments for COVID-19, has been extrapolated 
from experience with SARS, MERS or limited to case-series [10] [11]. Rando-
mized-controlled trials are ongoing, most notably with three agents: 1) Remde-
sivir, actually one of the novel investigational drugs with possible greatest poten-
tial as an anti-Covid-19 [6] [12] [13] [14]. 2) Lopinavir/Ritonavir, an anti-retroviral 
used for treatment of HIV; [11] [12]. 3) Chloroquine and Hydroxychloroquine, 
antimalarial drugs with antiviral activity in-vitro, especially when associated 
with a macrolide antibiotic, azithromycin, in vivo [15] [16] [17]. All these have 
probably been the most mentioned and promising compounds for Covid19 
treatment. Other agents also under investigation including immunomodulatory 
drugs have been used to attenuate COVID-19-associated cytokine storm such as 
tocilizumab and sarilumab [18] [19] [20] as well as the mesenchymal stem cell 
therapy described by Atluri et al. (2020) [21]. 
2. The Macrolide-Clarithromycin Project 
By middle of March 2020, we presented to the Argentine National Health Min-
istry our novel idea to treat COVID-19 infected patients with only a Macrolide, 
Clarithromycin, as a single agent. Also, we proposed to use it for the prophylaxis 
of medical personnel largely exposed and at high risk. Even as a strategy to era-
dicate the virus from earth. In a way to rapidly make public this information and 
central idea: the use of clarithromycin as single agent for treatment and prophy-
laxis of COVID-19 we made a video and a special page for internet as well as a 
short preliminary communication on a special-scientific site of the web [22] [23] 
[24]. Until that date, in which we presented this project to our regulatory au-
thorities, and according to the available scientific literature and published in-
formation, no other research medical group in the world had previously done or 
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proposed a controlled clinical trial to test the pure antiviral efficacy of any ma-
crolide for COVID-19, as a single agent, without the association of any other 
drug with it. Up to date we have not received any answer yet from our Ministry 
of Health in this direction and in this short period of time several other groups 
from different parts of the world started thinking in similar but not identical 
ideas.  
3. Other COVID-19 Interventional Studies with Macrolides 
As of May 3, 2020, the Cochrane COVID-19 Study Register lists 490 interven-
tional studies of which 285 are randomized trials [25]. In the  
https://www.ncbi.nlm.nih.gov/pubmed site there are 7947 published papers on 
Covid-19 [26] and at US ClinicalTrials.gov, which is a resource provided by the 
U.S. National Library of Medicine, only 3 clinical trials were found for macro-
lides, all for azithromycin and non for clarithromycin, but only one using azith-
romycin as single agent for Covid-19 [27]. This is a short description of these 
trials: 1) Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With 
Suspected or Confirmed COVID-19 (HAHPS). This is a Phase 2 randomized 
Intervtional study in which 300 patients will be enroll. Patients in the Hydrox-
ychloroquine arm will receive Hydroxychloroquine 400 mg by mouth twice daily 
for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for 
weight < 45 kg or GFR (glomerular filtration rate) < 50 ml/min). Patients in the 
Azithromycin arm will receive Azithromycin 500 mg on day 1 plus 250 mg daily 
on days 2 - 5 (may be administered intravenously per clinician preference). If the 
patient has already received azithromycin prior to randomization, the prior dos-
es will count toward the 5 day total. It is now recruiting. It was First Posted : 
April 1, 2020, and it is done by the University of Utah (ClinicalTrials.gov Iden-
tifier: NCT04329832) [28]. 2) Azithromycin for COVID-19 Treatment in Outpa-
tients Nationwide (ACTION). This individually randomized telemedicine-based 
trial organized by University of California, San Francisco will evaluate the effi-
cacy of a single dose of 1 gr Azithromycin for prevention of progression of 
COVID-19 in patients with a recent positive SARS-CoV-2 test who is not cur-
rently hospitalized. Was First Posted on April 2, 2020 and is not still recruiting 
patients. They have an estimated enrollment of 2271 participants. They propose 
an individually-randomized, placebo-controlled trial to determine the efficacy of 
a single dose of 1gr Azithromycin for prevention of COVID-19 progression to 
hospitalization (ClinicalTrials.gov Identifier: NCT04332107) [29]. 3) Azithro-
mycin in Hospitalized COVID-19 Patients (AIC). The present study is a rando-
mized, double-blind, controlled, clinical trial, with the approval of the ethics 
committee will be conducted on patients who have a positive test confirming 
COVID-19 in Shahid Modarres Medical Education Center and Hospital in Te-
hran. Patients will be randomly assigned to the two arms of the study and after 
completing the course of treatment and collecting and analyzing the necessary 
information from each patient, the results of the study will be published both on 
this site and in the form of an article in a reputable international journal. It is 
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not yet recruiting and was First Posted on April 24, 2020. Shahid Modarres Hos-
pital, Shahid Beheshti University of Medical Sciences and Health Services. Te-
hran, Iran, Islamic Republic of, (Clinical Trials.gov Identifier: NCT04359316) 
[30]. No paper or study at this time was found either in any of these sites for 
Clarithromycin and COVID-19 [25] [26] [27]. 
4. General Mechanism of Action of Macrolides 
The macrolide family of antibiotics is widely used for bacterial infections and 
especially those produced by Mycoplasmas and Atypical bacteria. They include 
several drugs such as erythromycin, azithromycin, clarithromycin, and telithro-
mycin between others [31] [32]. Side effects of these drugs are rare but may in-
clude stomach upset, diarrhea, nausea, vomiting, or abdominal pain. Much more 
less common but serious side effects include hearing damage or deafness, 
drooping eyelids and blurred vision, difficulty swallowing or speaking, muscle 
weakness, and liver damage. It is contraindicated for people allergic to erythro-
mycin, clarithromycin, azithromycin and/or telithromycin. It is also contraindi-
cated in people with severe liver and kidney disease [33]. Clarithromycin is sev-
eral-fold more active in vitro than Erythromycin against gram-positive organ-
isms, while Azithromycin is 2- to 4-fold less potent. Clarithromycin has a longer 
serum half-life and better tissue penetration than erythromycin, allowing 
twice-a-day or once-a-day long acting formulation dosing for most common in-
fections [32] [33]. In addition to common bacteria, Azithromycin and Clarith-
romycin have demonstrated to be also active as single agents against some un-
expected pathogens (e.g., Borrelia burgdorferi, Toxoplasma gondii, Mycobacte-
rium avium complex, and M. leprae), Zica Virus and maybe also, against 
SARS-CoV-2 as we are postulating [34] [35] [36] [37]. Efficacy of Clarithromy-
cin has been examined against H5N1 highly pathogenic and H7N9 low patho-
genic avian influenza virus infections in cynomolgus monkeys, showing viral 
suppression and clinical improvement [38] [39]. A study assessed the efficacy 
and safety of a Clarithromycin-Naproxen-Oseltamivir combination for the 
treatment of serious influenza, also showing good results reducing both 30- and 
90-day mortality and length of hospital stay [40]. 
Clarithromycin is also used in conjunction with other medications to treat 
stomach ulcers caused by Helicobacter pylori [41]; and it has been used as an 
anti-cancer agent especially for Lymphomas [42]. 
It is usually administered as 500 mg oral dose every 12 hours or as a 500 mg 
long acting formulation once a day, both for 8 days [32]. 
It is several folds more active and has a better bioavailability than Azithromy-
cin (55% vs. 37%), it is resistant to gastric acid and its absorption and bioavaila-
bility are enhanced by food (70% vs. 55%) while a decrease of 52% is recorded 
for Azithromycin, its metabolite in human, the 14-Hydroxy-Clarithromycin, is 
also microbiologically active thus enhancing the activity of the parent molecule, 
it reaches peak serum concentration faster than Azithromycin (1.8 hr. vs 2.5 hr.), 
it attains higher peak concentration than Azithromycin (3 mg/L vs 0,4 mg/L) 
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and it has a better concentration in the nasal mucosa, tonsils and lung tissue [33] 
[43]. 
5. Macrolides as Antivirals 
The novel antiviral mechanism of action of macrolides was discovered when a 
significant improvement in the survival of patients with diffuse pan-bronchiolitis 
(DPB) receiving low dose of Erythromycin was observed, and when their benefi-
cial effect was found to be independent of their anti-microbial activity. Their 
administration was associated with reduced inflammatory response in chronic 
airway diseases including upper and lower respiratory tract infections [44] [45]. 
6. Clarithromycin as an Antiviral 
Both in vitro and in vivo studies have provided evidence of their efficacy in viral 
respiratory infections including rhinovirus (RV), respiratory syncytial virus 
(RSV), and influenza virus [45]-[53]. 
Clarithromycin can inhibit the duplication of some influenza viruses. In con-
centrations of 12.5 and 25 μg/mL, this drug reduces the duplication of H1N1 in-
fluenza virus in vitro [54].  
It acts at the middle and late stages of virus replication to reduce the duplica-
tion of progeny virus in the infected cell [55].  
In the early stage of virus infection (2 - 3 d), the secretion of IL-12 is increased 
to promote the production of interferon (IFN)-γ and immunoglobulin (Ig) A on 
the mucous membrane of the respiratory tract in order to enhance the immunity 
of the mucous membrane [56] [57] [58]. During the middle and late stages (after 
6 d) of a deadly influenza infection model, excess IFN-γ is produced (59). The 
clinical significance of reducing this immune reaction and its ability to affect the 
fatality rate are currently being investigated and are expected to be future targets 
of Macrolide therapy [60] [61]. 
Clarithromycin as well as other macrolides can inhibit the activation of NF-κB 
in cell nuclei to reduce transcription and promote anti-inflammatory action 
[59].  
In summary, clarithromycin, a clinically used macrolide, reduces FluA viral 
titers and cytokines secretion in supernatant fluids, FluA virus RNA replication 
in the cells, and susceptibility of the cells to infection by the virus [62] [63] [64]. 
Clarithromycin also reduced the expression of SA 2,6Gal, a receptor for hu-
man influenza, on the mucosal surface of human tracheae, and reduced the 
number of acidic endosomes from which viral RNPs enter into the cytoplasm 
[63]. 
Those clarithromycin mechanisms were explained by actions on inhibition 
protein synthesis by reversibly binding to the 50S ribosomal subunits. This ac-
tion share with the macrolides that inhibit the translocation of aminoacyl trans-
fer-RNA, and prevents peptide chain elongation. Perhaps this may could acting 
and explaining the antiviral properties; the SARS-CoV-2 is an RNA virus [65] 
[66]. 
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Otherwise, the macrolide antibiotics, especially Clarithromycin can decrease 
the hypersecretion of proinflammatory cytokines and chemokines in vitro, in 
preclinical models, and chronic inflammatory pulmonary diseases. Other pro-
prieties of the macrolides that could aid their action in pulmonary injuries are 
the airway epithelial barrier that is due to the stabilization of the epithelial cell 
membrane, the entry of the virus into the cell [67].  
All these findings suggest that a clinically used macrolide antibiotic, clarith-
romycin, may inhibit many virus, including type A seasonal human influenza 
virus infection, via reducing its receptor on the airway epithelial cells and via 
reducing entry of viral RNPs, which contain viral RNA, into the cytoplasm [57] 
[68] [69]. 
Macrolides have received considerable attention for their anti-inflammatory 
and immunomodulatory actions beyond the antibacterial effect. These two 
properties may ensure some efficacy in a wide spectrum of viral infections [70] 
[71] [72] [73]. They downregulate the inflammatory cascade, attenuate excessive 
cytokine production in viral infections, and they may reduce virus-related ex-
acerbations [72] [73]. The effects of Clarithromycin in patients with Covid-19 
and pulmonary disease appear to be also independent of its antimicrobial prop-
erties, and maybe more related to immunomodulating pathways that do not af-
fect its antibiotic mechanism. This action could also be required for COVID-19 
as there are many descriptions of “cytokines storms” syndromes [67] [68] [69] 
[70] [73]. 
Clarithromycin inhibit airway inflammation and may modulate also the se-
verity of influenza infection induced by influenza virus infection. [71]. 
Much data showed that macrolides reduced different viral titers of ICAM-1, as 
well as the release of many pro-inflammatory viral infection-induced cytokines 
including IL-1β, IL-6, IL-8, and TNF-α. Also, lowering of viral titers and RNA of 
viral replication as well as augmentation of the IL-12 by macrolides, which is es-
sential in reducing virus yield were revealed [59] [62] [64]. The demonstration 
that the macrolides, particularly clarithromycin, have a role on immunomodula-
tion, could also be seen in the potential case of a patient receiving a mesenchym-
al cell therapy simultaneously attenuating pro-inflammatory cytokines secretion, 
inflammatory cell recruitment and/or increased alveolar macrophages content 
specially if that patients could have respiratory distress [21] [73] [74]. 
Based on all this existing evidence, macrolides, especially Clarithromycin 
maybe considered as a promising treatment option in treatment of respiratory 
viral infections and have encouraged a number of researchers to explore further 
this potential application even us for Covid-19 Treatment and Prophylaxis [22] 
[23] [24] [74] [75]. 
Azithromycin pharmacologically is very similar to Clarithromycin [32], but, 
according to our experience and that of the scientific literature, Clarithromycin, 
as an antiviral, anti-inflammatory and/or immunomodulatory drug seems to be 
a lot much better [22] [23] [33] [34] [74] [75]. 
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That’s why it should be better or even essential to use Clarithromycin in any 
proposed trial of this kind in which a Macrolide would be given as a single agent. 
7. Macrolides Used for MERS 
In patients with Middle East Respiratory Syndrome (MERS), macrolides are of-
ten prescribed as part of the empiric treatment regimen for pneumonia, often 
before the detection of MERS coronavirus (MERS-CoV). Using a cohort of crit-
ically ill patients with MERS, the aim of one study was to determine whether 
there was an association between macrolide therapy and 90-day mortality and 
RNA clearance in critically ill patients with MERS. Of 349 critically ill MERS pa-
tients, 136 (39%) received macrolide therapy. Azithromycin was most common-
ly used (97/136; 71.3%). Macrolide therapy was commonly started before the pa-
tient arrived in the intensive care unit (ICU) (51/136; 37.5%), or on day1 in ICU 
(53/136; 39%). Patients received macrolide treatment (Azithromycin, Clarith-
romycin) within three days before admission to ICU, or at any time during their 
stay in ICU, up to 28 days and a “no macrolide therapy” (control) group. Macro-
lide therapy was not independently associated with a significant difference in 
90-day mortality or improvement in MERS-CoV RNA clearance [76]. But due to 
the nature of the population of this study (critically ill patients), this study did 
not measure the difference in symptoms improvement between the group who 
received macrolides and the group who did not. Also, the category of these pa-
tients as they were all critically ill, might have not been, the best one to start with 
this kind of treatment. If the patients could have received the treatment before 
being critically ill maybe the results could have been completely different. Also, 
this study was a retrospective one. 
8. The French Studies with Hydroxychloroquine and the  
Macrolide Azithromycin for COVID-19  
The small studies using the combination of Hydroxychloroquine and Azithro-
mycin “showed a significant reduction in viral load” after six days of treatment 
and a “much shorter average viral load duration” compared to patients who re-
ceived another treatment. Six patients in one of the trials were asymptomatic 
and 22 had symptoms of upper respiratory tract infection. Eight patients had 
lower respiratory tract infections. Twenty cases were treated in the study, with 
untreated patients acting as negative controls. Hydroxychloroquine treatment 
was found to significantly reduce viral load in patients with COVID-19, and had 
an improved effect when azithromycin was included in the treatment. Interes-
tingly, a patient who continued to test positive after being treated with Hydrox-
ychloroquine alone was given Azithromycin starting on the eighth day and 
tested negative the following day [79]. 
This fact is of outmost importance since it would be inferred from said results 
that macrolide drugs could have an antiviral effect inherent to them. 
However, Hydroxychloroquine an antimalarial and antirheumatic drug has 
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many adverse reactions such as cardiac, liver and eye disorders among others. 
Thus, checkups are needed before using Hydroxychloroquine in patients with 
chronic diseases who are the most affected by COVID-19 [16] [17] [78] [79] 
[80]. 
This risk could have been lowered by using Hydroxychloroquine at a lower 
dosage but still achieving a good, and more stable concentration in the blood. 
This fact could have been better achieved combining Hydroxychloroquine with 
Clarithromycin which is in many ways superior to Azithromycin [33] [81]. 
Also, that risk is no longer a problem, if Hydroxychloroquine is not used in 
such a combination and, any macrolide specially Clarithromycin alone could be 
left as a single agent as we have postulated [22] [23] [24]. 
It has been usually wrongly believed that azithromycin, in all those different 
COVID-19 clinical studies, has mainly acted as an antibacterial agent especially 
for associated-pneumonias [77] [78] [81]. 
When comparing the effect of Hydroxychloroquine treatment as a single drug 
and the effect of Hydroxychloroquine and Azithromycin in combination, the 
proportion of patients that had negative PCR results in nasopharyngeal samples 
was significantly different between the two groups at days 3 - 4 - 5 and six 
post-inclusion. At day six post-inclusion, 100% of patients treated with Hydrox-
ychloroquine and Azithromycin combination were virologicaly cured comparing 
with 57.1% in patients treated with Hydroxychloroquine only, and 12.5% in the 
control group (p < 0.001). Of note, one patient who was still PCR-positive at day 
6-post inclusion under Hydroxychloroquine treatment only received Azithro-
mycin in addition to hydroxychloroquine at day eight post inclusion and cured 
her infection at day-9 post-infection [77] [78]. 
9. How Did Hydroxychloroquine and Azithromycin Worked  
Together and Could Have Azithromycin Been the Most  
Active Drug in That Combination? 
The results obtained in those Hydroxychloroquine-Azithromycin studies [77] 
[78], could only be explained by three simple possible ways: 
1) Azithromycin only acts as an antibacterial agent for associated pneumonia; 
2) Azithromycin acts synergistically with Hydroxychloroquine; 
3) Azithromycin has an antiviral effect independent of that of Hydroxychlo-
roquine. 
No one has come out to completely open the scene on this yet. “From all the 
cited scientific literature and our own clinical experience we are more inclined to 
think that the action of macrolides in these situations could have been basically 
antiviral” [22] [48]. 
10. Other Studies Indicating That Clarithromycin Is a Good  
Option for COVID-194. General Mechanism of Action of  
Macrolides 
Another exciting study made in Iran, experienced docking experiments using 
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the newly released coordinate structure for COVID-19 protease as a receptor 
and nine drugs were selected from HIV-1 protease inhibitors and twenty-one 
candidates from anti bronchitis drugs, based on their chemical structures and 
enrolled them in blind and active site-directed dockings in different modes and 
native-like conditions of interactions. These experiments suggested that the 
binding capacity and the inhibitory potency of those candidates were as follows: 
Tipranavir > Indinavir > Atazanavir > Darunavir > Ritonavir > Amprenavir for 
HIV-1, and Cefditoren > Cefixime > Erythromycin > Clarithromycin for an-
ti-bronchitis medicines [82]. In this context the author imagines that a successful 
treatment regime should contain multi drugs of protease inhibitors, spike shiel-
ding drugs, and immunomodulatory drugs in early steps of the disease and 
Ivermectin > heparin (as intravenous or nebulized) > macrolides seemed to 
them to be good adjuvant candidates in all anti 2019-nCov regimes to shield S 
protein even for prophylactic purposes [83]. 
Other small experiences appeared in the scientific literature later on in a 
similar direction. One study in Taiwan, reported two cases with communi-
ty-acquired pneumonia caused by severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) who returned from Wuhan, China. In hospital, one patient 
positive for the virus remained febrile, malaise and poor appetite. Follow-up 
CXR revealed increasing opacity at right middle and lower lung fields. Levoflox-
acin was initiated. On hospital day 12, after a 6-day course of Levofloxacin, her 
fever abated with improved appetite and physical activity. She became free of 
symptoms afterward. The second patient on day 6 in hospital, remained febrile, 
malaise and poor appetite. She reported worsening of cough. Follow-up CXR 
revealed patchy consolidation over bilateral lower lung field. Parenteral Cefe-
pime and oral Clarithromycin therapy were initiated. On day 9, she was afebrile 
with improved general condition. Antimicrobial therapy was shifted to oral 
Moxifloxacin. She remained free of symptoms afterward [84]. 
In Colombia, as published, one patient received clarithromycin instead of 
azithromycin, in combination with chloroquine with the successful recovery of 
COVID-19 pneumonia, without any side adverse effects and become negative 
for the SARS-CoV-2 infection, as observed in the RT-PCR test [85].  
In Ecuador 12 patients were treated with a combination of Clarithromycin, 
N-acetilcystine and an antiviral nutraceutical (Virusid) with excellent outcomes 
[86]. 
Clarithromycin should be the best candidate to be tried for COVID-19 from 
all this evidence is obvious for us. 
11. “The Macrolide-Clarithromycin Task-Force for the  
Treatment and Prophylaxis of COVID-19” 
Scientists and clinicians especially in Latin American countries, have many dif-
ferent difficulties, mainly economical, to implement innovative concepts in 
Medicine or to carry on control clinical trials. Also, it seems that we are bound 
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to many bureaucratic barriers and very slow motion of our health authorities to 
test novel medical strategies in this urgent situation.  
However, as it is observed in Brazil, our countries and people could be dam-
aged more strongly by the virus than in other parts of the world and maybe suf-
fering the worst consequences even in a second possible wave of this virus [87].  
For this purpose, we have interested and joined several medical groups from 
different South and Central American countries in what we have called the 
“Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of 
COVID-19”.  
The main objective of this Task-Force is to use a Macrolide: Clarithromycin, 
as a single agent for the treatment and prophylaxis of the COVID-19 pandemic 
and perform a multi-national collaborative project and at least two controlled 
Clinical Trials in this direction: one therapeutic and the other prophylactic. 
With this novel concept in mind, that Clarithromycin could not only be an 
antibacterial agent but also a strong immunomodulatory, anti-inflammatory and 
anti-viral one, very active for COVID-19, the authors from Argentina, Mexico, 
Peru, Brazil, Colombia, Ecuador, and Venezuela of this review propose two 
Protocols for Covid-19 for Profilaxis and Treatment. 
This Task Force is now opened to all the interested groups not only in Latin 
America but also from the rest of the world, such as it was the case of Iran that 
early joined the Force. Also, the United States has been invited to participate. 
12. Extenuating Clinical Circumstances and the Possible Use  
of Clarithromycin 
It is well recognized that there may be extenuating clinical circumstances where 
clinicians decide to use unproven therapies when clinical trials are unavailable. 
In those circumstances where unproven therapies are used, the WHO has pro-
vided a standardized case report form for data collection to ensure that there is a 
contribution to scientific research and the clinical community [88].  
As with any viral pneumonia, COVID-19 itself up to here has not been an 
indication for antibiotics. However, patients who present with respiratory 
symptoms and pulmonary infiltrates on imaging may meet the diagnostic crite-
ria for COVID-19 and Bacterial Pneumonia or just Bacterial Pneumonia without 
COVID-19 when the diagnostic tests are done and the results are obtained. 
Typical or Atypical pulmonary Infection without COVID-19 or COVID-19 with 
pulmonary co-infection with any bacterial pathogen can be possible, and as per 
standard therapy, antibiotics should be indicated in both situations. Losing time 
until the initial antibiotic treatment or non-response to initial antimicrobial 
therapy will increase mortality in both situations. Then, the initial and urgent 
selection of antimicrobials is critical. According to NICE [89], to cover atypical 
and multiple pathogens in older patients with pneumonia and at risk of severe 
complications, the recommended choices of antibiotics in the community are 
shown in Table 1. 
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Table 1. Recommended choices of antibiotics. 
Amoxicillin with 
500 mg 3 times a day 
(higher doses can be used – see BNF) for 5 days 
Clarithromycin (if atypical pathogens) 500 mg twice a day for 5 days 
 
An example of standard therapy for in-patient treatment for community ac-
quired pneumonia is ceftriaxone 1 - 2 g IV daily with a macrolide, usually azith-
romycin 500 mg IV/PO × 3 days or azithromycin 500 mg PO × 1 day followed 
by 250 mg PO × 4 days [89].  
In these situations, in the context of the COVID-19 pandemic, with or with-
out prior testing results, especially in poor undeveloped countries, we propose to 
urgently use in patients with cough and fever with or without signs and images 
of pneumonia, as first choice, a Macrolide, the Clarithromycin antibiotic, not 
only as an anti-bacterial but also as an antiviral, anti-inflammatory, and im-
mune-modulating agent.  
Apart from penicillin allergy, adverse reactions to the recommended antibio-
tics, e.g. macrolides, are generally mild and uncommon. The main disadvantage 
of this proposed strategy is that it could tend to drive increased bacterial resis-
tance. However, in a pandemic like this one, with a high mortality rate in a spe-
cific subpopulation, in this case the very elderly people, this needs to be weighed 
against the benefits of the policy [88] [89]. 
If Clarithromycin could have the desired anti SARS-CoV-2 effect, then, rescue 
prescribing strategies, initiated by the own patient at an early stage with this 
macrolide Clarithromycin, could aid effective delivery not only of an outstand-
ing antimicrobial but also of an antiviral in the same tablet, significantly reduc-
ing hospital admissions, and lowering mortality. 
While less antimicrobial resistance should remain a global priority, the cur-
rent pandemic highlights the need for unprecedented management strategies. 
For example, in the current context, it may be entirely appropriate for nursing 
homes to have routine stockpiles of antibiotics [89], but as we have said, specifi-
cally clarithromycin. Rapid interventions like this could be life-saving, allowing 
rapid and appropriate prescribing decisions that could minimize morbidity and 
mortality of COVID-19, as well as reducing the impact of the pandemic on 
health services most exposed to this virus. 
In this context, equipping patients and medical personnel in the first lines 
with rescue clarithromycin for Primary Prophylaxis as we have proposed for the 
first time, may be a legitimate strategy to consider in this pandemic, and should 
be tried in a Controlled Clinical Trial. 
13. Primary Purposes of Our Two Proposed Protocols for  
Covid-19 
13.1. Treatment 
Objective: To detect and early diagnose a possible new case of coronavirus 
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(COVID-19) patient and even healthy carriers, in order to allow their inclusion 
in a research protocol with the exclusive use as single agent, of Clarithromycin 
500 mg long acting oral formulation that allows its administration once a day for 
8 days and see if this treatment per-se is able to reduce and/or disappear the viral 
load in that new case or healthy carrier and stop the progression of the disease to 
more severe stages, as well as lowering mortality. 
13.2. Primary Prophylaxis 
Current evidence suggests that person-to-person spreading among first-line 
healthcare workers caring for patients suffering from COVID-19 is a dangerous 
situation that could leave people without primary or specialized care and treat-
ment. So far, no drugs or combinations have been fully recommended, nor are 
vaccines approved for the use of antiviral prophylaxis before or after exposure to 
COVID-19 available, since there is no evidence to support their use yet. 
Objective: to test the Clarithromycin 500 mg long acting oral formulation that 
allows its administration once a day for 15 days as a single agent could have a 
prophylactic effect on members of the health team directly involved in the care 
of patients with COVID-19 and highly exposed to this virus, reducing the possi-
bility of their infection as well as progression, and permitting to protect them-
selves. 
14. Discussion 
Considering the amount of death and the catastrophic consequences in the glob-
al economy that this COVID-19 pandemic is leaving behind all over the planet, 
we think this strategy is worth convenient to at least be tried in controlled clini-
cal trials.  
Clarithromycin could change the history of this disease. It could reduce the 
costs of treatment and the potential adverse effects when combining more than 
one drug such as with Hydroxychloroquine. Clarithromycin treatment as a sin-
gle agent could be much more simple, safe and cheaper as giving Chloroquine or 
Hydroxychloroquine alone or in combination with Azithromycin as well as oth-
er therapeutic options. 
Clarithromycin would be immediately available globally and could protect all 
health workers from COVID-19. It would avoid patients to be sent to Intensive 
Care Units if used as soon as they start with the first symptoms or even at diag-
nosis in asymptomatic patients. It would reduce the high mortality rate asso-
ciated with the disease. It would accelerate the inactivation of the viral load. I 
would avoid the economic debacle of the world. 
If these results would be encouraging, it could then be possible to propose 
to the governments of the world to quickly implement a whole-earth-all-persons 
treatment-prophylaxis strategy with Clarithromycin as a single agent, to reduce 
the mortality, and maybe eradicate the virus from our planet. This proposition 
would keep waiting for the development of vaccines, as they are not available at 
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the moment and need to follow the course of the research phases, especially to 
completely ensure the safety of humanity. 
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